AzacitidineAntimetabolites, AntineoplasticMyelodysplastic SyndromesTreatment OutcomeLeukemia, Myelomonocytic, ChronicDrug Administration SchedulePilot ProjectsDrug Therapy, CombinationFluorenesChromatography, Supercritical FluidDrug CombinationsPiracetamAdministration, OralDermatologic AgentsCompassionate Use TrialsDouble-Blind MethodInjections, SubcutaneousLeukemia, Myeloid, AcuteArtemisininsEthanolaminesAnemia, RefractoryConsolidation ChemotherapyProspective StudiesCross-Over StudiesInduction ChemotherapyAnemia, Refractory, with Excess of BlastsFollow-Up StudiesTime FactorsAntirheumatic AgentsDrug ApprovalInfusions, IntravenousDose-Response Relationship, DrugSpin LabelsSeverity of Illness IndexRecurrenceDNA MethylationDNA Modification MethylasesAntimalarialsDelayed-Action PreparationsSurvivalSingle-Blind MethodUnited States Food and Drug AdministrationInternational AgenciesEpigenomicsThalidomideAffinity LabelsAnticonvulsantsArea Under CurveOpen Reading FramesMalaria, FalciparumRemission InductionAntineoplastic Combined Chemotherapy ProtocolsBiological AvailabilityAntimetabolitesImmunosuppressive AgentsBlood TransfusionCytarabineTetrazolium SaltsLeukemia, MyeloidChronic DiseaseRetrospective StudiesAntihypertensive AgentsMaximum Tolerated DoseRandomized Controlled Trials as TopicAcute DiseaseFatigueSurvival AnalysisEnzyme InhibitorsCell Line, TumorHematopoietic Stem Cell TransplantationDisease ProgressionTransplantation, Homologous